Skip to main content

Table 3 Prevalence of ermF and ermB macrolide resistance genes over time

From: Prevalence and abundance of selected genes conferring macrolide resistance genes in COPD patients during maintenance treatment with azithromycin

 

ermF

% (pos/all samples)

ermB

% (pos/all samples)

Prevalence

Placebo

Azithromycin

P value

Placebo

Azithromycin

P value

Baseline

44,4 (16/36)

59,1 (26/44)

0.261

86,1 (31/36)

97,7 (43/44)

0.085

M6

43,3 (13/30)

67,6 (23/34)

0.050

80,0 (24/30)

97,1 (33/34)

0.029*

M12

48,1 (13/27)

68,8 (22/32)

0.109

74,1 (20/27)

100,0 (32/32)

0.002*

  1. *Prevalence of ermB is statistically significant in the Azithromycin group at M6 and M12 compared to the Placebo group (Chi-square, Pearson corrected)
Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us